37 results about "Influenza (flu)" patented technology

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

The application discloses a recombinant nanobody against swine influenza virus of H1N1 subtype, and a preparation method and application thereof, and belongs to the field of biological medicines. A VHH sequence of the nanobody against swine influenza virus of H1N1 subtype is screened from a nanobody bacterial library of an immunized llama, the VHH sequence is directionally cloned into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, and the recombinant eukaryotic expression plasmid is transformed into a Pichia pastoris expression system to screen an expression engineering strain, and the recombinant nanobody is obtained after induction culture of the expression engineering strain. It is proved by in-vitro and in-vivo experiments that the recombinant nanobody developed in the application can neutralize CA / 04 and has a remarkable therapeutic effect. Therefore, the neutralizing nanobody provided in the application has considerable potential in treating CA / 04. The findings will provide experimental data for developing nanobody preparations against swine influenza virus of H1 subtype and provide a new strategy for preventing and controlling swine influenza.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

The invention relates to an anti-influenza compound as well as a preparation method and application thereof, and the anti-influenza compound has a structure as shown in formula (I): (I) wherein X1 is CR3 or N; x2 is CR4 or N; z is CR5 or N; y1 is CR6 or N; y2 is CR7 or N; y3 is CR8 or N; w is-NH-or-N = CH-; in the formula, R1 is-R < 9 >-COO < 10 >,-(CR < 122 >) < n >-R < 11 >-(CR < 122 >) < n >-O-H,-(CR < 122 >) < m >-O-H,-(CR < 122 >) < h >-COO < 10 > or-R < 11 >-CONR < 13 >-R < 14 >. The compound provided by the invention has strong inhibitory activity on influenza virus, and is subjected to in-vivo antiviral activity test, action mechanism analysis and pharmacokinetic characteristic evaluation at the same time.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

To provide a prophylactic and therapeutic agent for viral respiratory infectious diseases comprising a new component.SOLUTION: The features of the present invention for solving the above problems are as follows. 1. A prophylactic or therapeutic agent for viral respiratory infection, comprising glucosylceramide and / or glucosylceramide as an active ingredient. (2) A prophylactic or therapeutic agent for viral respiratory infections, which comprises β - sitosterol glycoside as an active ingredient. (3) The prophylactic and therapeutic agent for viral respiratory infection according to (1) or (2) above, wherein the viral respiratory infection is influenza.SELECTED DRAWING: None

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The invention provides a combined medicine composition for treating brain glioma and application. The medicine composition comprises a copper ion carrier and a targeted NEU1 anti-influenza medicine. According to the combined medicine composition, an effective medicine combination strategy is provided for treatment of the brain glioma, and the combined medicine composition comprises a copper ion carrier, namely the illicit and an anti-influenza medicine, namely the oseltamivir. According to the invention, the condition that the combination of the ilismos and the oseltamivir has a synergistic effect on the treatment of the brain glioma is found for the first time.

The application relates to application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs and belongs to the technical field of medicines. The application provides application of dihydroergotamine mesylate in preparation of anti-influenza virus drugs. The dihydroergotamine mesylate can play a role in an early replication stage after influenza virus enters a host cell, can inhibit synthesis of influenza virus nucleic acid, can significantly improve lung symptoms caused by influenza A, reduces virus titer in lung tissues, has good cell safety, biological safety and effectiveness, and has a good anti-virus application prospect.

The present invention relates to an imidazopyridine derivative and a pharmaceutical composition comprising same as an active ingredient and, more particularly, to an imidazopyridine derivative that inhibits protein kinase activity and as such, can be used for preventing or treating cancer, neurodegenerative disease, non-alcoholic fatty liver disease, influenza, etc., and a pharmaceutical composition comprising same as an active ingredient.

To provide a composition for treating and / or preventing influenza, food and drink, and feed, which are excellent in safety as well as preventive effect and treatment effect.SOLUTION: The present disclosure provides a composition for treating and / or preventing influenza containing a retinoid compound as an active ingredient.SELECTED DRAWING: Figure 2

A topical composition comprising a nanonised L-glutathione and cyclodextrin complex, together with ascorbic acid in a weight ratio of glutathione to ascorbic acid from 7:1 to 15:1 and from 1:1 to 1:15 and a further compound comprising dexpanthenol, thiamine, benzalkonium chloride, sodium hyaluronate or acetyl-L-cysteine, which composition is topically administered for treating the symptoms of viral infection including COVID-19 and influenza, and for treating herpes simplex, herpes zoster, post herpetic neuralgia, genital herpes, alcohol detoxification, high triglycerides, age or liver spots and lupus.

The present disclosure relates to compositions comprising RNA molecules encoding influenza-derived antigens, where the RNA may be formulated in lipid nanoparticles (LNPs), and the compositions further comprise a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or an RNA molecule encoding an antigen derived from RSV, where the RSV RNA may be formulated in LNPs. The present disclosure further relates to the use of RNA molecules, RNA-LNPs, and compositions for the prevention of influenza and RSV infection-induced illnesses.

The invention belongs to the field of medicines, and discloses a ganoderma triterpenic acid compound, a preparation method thereof and application of the ganoderma triterpenic acid compound in prevention and treatment of influenza viruses. The ganoderma triterpenic acid compound (24E)-3alpha-hydroxy-7-oxo-lanosta-8, 24-dien-26-oic acid is as shown in a formula I which is described in the specification. Experiments prove that the compound disclosed by the invention has relatively good influenza virus neuraminidase inhibitory activity, and the IC50 of the compound is 18.3 mu M. Researches show that the compound has an application prospect in further development of novel anti-influenza drugs.

This invention relates to the fields of deep data fusion and machine learning technology, and provides a method and system for dynamic early warning of pneumonia risk in influenza patients. The method includes acquiring influenza-related data and constructing an influenza dataset; dividing the influenza dataset into structured data and unstructured image data; forming a standardized multimodal feature dataset; inputting the standardized multimodal feature dataset into a bidirectional modality-aware attention network and an adversarial cross-modal alignment network for deep fusion and semantic alignment processing to form an aligned unified feature representation; inputting the aligned unified feature representation into a downstream prediction network, and after risk probability calculation and threshold judgment processing, forming a risk level and corresponding personalized early warning information and clinical auxiliary suggestions. This invention improves the accuracy and practicality of early warning of pneumonia risk in influenza patients through comprehensive processing, deep fusion, accurate assessment, and personalized early warning of multimodal data.

THIS invention relates to the synthesis of derivatives of siphonochilone and therapeutic use thereof in the treatment and CN prevention of respiratory virus disease, in particular influenza or a coronavirus disease.

The invention provides an influenza risk index construction and evaluation method based on multi-source monitoring data. The method comprises the following steps: firstly, collecting data of influenza detection, respiratory infectious diseases of outpatient and emergency treatment and hospitalized respiratory infectious diseases of medical institutions by means of a city intelligent early warning platform, acquiring influenza-related search data by using a Baidu interface, and preprocessing to eliminate data differences and missing; thirdly, a possibility risk index is constructed and obtained through weighted summation of three sub-indexes including the influenza detection positive rate and the like, and meanwhile the respiratory tract related hospitalization rate serves as a severity risk index; afterwards, according to a risk grade division standard, the possibility and severity risk grades are comprehensively evaluated through a risk matrix method, and the comprehensive risk grade of the influenza is determined. The method is wide in data source and comprehensive in evaluation index, can dynamically and quantitatively evaluate the influenza risk, provides a scientific basis for public health decision making, assists influenza prevention and control, and has a wide application prospect.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of PHA-767491 or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating H1N1 subtype swine influenza. In-vitro cell experiments show that the GPCR small molecule compound PHA-767491 has a remarkable inhibition effect on the H1N1 subtype swine influenza virus, the median inhibitory concentration (IC50) of the GPCR small molecule compound is 0.16 M, and the median cytotoxic concentration (CC50) of the GPCR small molecule compound is greater than 200M. When the medicine is administrated when H1N1 subtype swine influenza virus infection is carried out, the inhibition rate exceeds 88%. In-vivo animal experiments show that the PHA-767491 can effectively protect mice from being attacked by the H1N1 subtype swine influenza virus, the death rate is remarkably reduced, and clinical symptoms are relieved. The PHA-767491 can be used as an effective component to prepare a new drug for preventing and treating the H1N1 subtype swine influenza, and has a wide application prospect.

The invention discloses application of akebia quinata phenylethanoid glycoside B in preparation of a product for preventing and treating influenza virus infection, and relates to the technical field of biological medicines. Through molecular docking screening, cytotoxicity experiments and antiviral activity verification, the application value of the akebia quinata phenylethanoid glycoside B in prevention and treatment of influenza virus infection is defined, and the technical effect is remarkable. In the aspect of safety, the akebia quinata phenylethanoid glycoside B has no obvious influence on the survival rate of MDCK cells under high concentration, is far higher than clinical potential medication concentration, has no obvious cytotoxicity and is good in biocompatibility. In the aspect of antiviral activity, the akebia quinata phenylethanoid glycoside B shows an efficient inhibition effect on influenza viruses, the IC50 value is as low as 28.5 mu M, and the inhibition effect is superior to that of part of natural components and oseltamivir. In an application scene, the akebia quinata phenylethanoid glycoside B can be prepared into various drug dosage forms and can also be used as an active ingredient of a disinfectant, and a novel safe, efficient and multifunctional influenza prevention and control scheme is provided for the field of biological medicine.

The invention discloses a traditional Chinese medicine nano composition as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine preparations. The preparation method comprises the following steps: mixing the traditional Chinese medicine raw materials according to the formula ratio, soaking with water, decocting, and filtering with gauze to obtain filtrate; performing differential centrifugation on the filtrate, and taking supernatant; carrying out ultracentrifugation on the supernatant and then taking a precipitate; and resuspending the precipitate with water to obtain the traditional Chinese medicine nano composition. Wherein the traditional Chinese medicine raw materials comprise radix bupleuri, pinellia ternate, codonopsis pilosula, liquorice, scutellaria baicalensis, ginger, jujube, ephedra, cassia twig, radix paeoniae alba, asarum, schisandra chinensis, rhizoma zingiberis, periostracum cicada, stiff silkworm, turmeric, rheum officinale and solidago decurrens. The traditional Chinese medicine nano composition provided by the invention is scientific in compatibility, has the effects of eliminating evil and strengthening the body resistance, not only aims at exterior syndromes of exogenous wind-cold and internal water retention, but also recuperates a shaoyang central machine and reconciles qi activity, realizes the comprehensive curative effects of relieving exterior and interior, regulating cold and heat and treating qi and blood simultaneously, and has remarkable treatment advantages on respiratory tract infectious diseases such as seasonal influenza.

The present application relates to the application of tetrahydrogestrinone in the preparation of anti-influenza virus drugs. The present application creatively finds that tetrahydrogestrinone has obvious inhibitory activity on influenza virus infection, targets NP through multiple modes of action to prevent influenza virus replication, and can effectively reduce the drug resistance of viruses. The present application repositions the drug function of tetrahydrogestrinone, further expands the indications, and reduces the time and cost spent in pharmacokinetic research and toxicity research, greatly reduces the research and development cost, can be used in the influenza treatment scheme more quickly compared with other anti-influenza drugs, and provides a potential treatment idea and reference basis for clinic.

The application discloses a rapid typing detection kit for influenza virus A and B. The application is based on the sequences of influenza virus A and B, and a primer and probe combination for simultaneously detecting multiple influenza virus A or B subtypes and distinguishing influenza virus A and B is designed. The application also provides a rapid typing detection kit for influenza virus A and B, which has the advantages of good detection specificity, high sensitivity and good accuracy, and the detection limit of influenza virus A / B nucleic acid can be as low as 50 copies / mL. The kit can be used for rapidly identifying whether a subject carries influenza virus A or B, and can distinguish influenza A patients, influenza B patients and uninfected people, and can also distinguish the rest of the virus infected patients, which is beneficial to the treatment of influenza patients and the prevention of influenza.

The present application relates to a kind of essential oil composition with the efficacy of improving immunity, belong to daily chemical technology field.The essential oil composition with the efficacy of improving immunity of the present application includes the following mass parts of components:Rowensha leaf essential oil 10-20 parts, eucalyptus essential oil 15-30 parts, green flower of guettarda speciosa essential oil 10-20 parts, guaiac essential oil 5-10 parts, cedar essential oil 5-20 parts.The essential oil composition with the efficacy of improving immunity of the present application can significantly reduce the secretion of TNF-alpha, and have certain inhibitory effect on streptococcus pneumoniae, haemophilus influenzae, in addition, also have certain antitussive efficacy, thereby verifying its efficacy of improving immunity, relieving respiratory discomfort.The composition of the present application can be used for preparing massage oil, aromatherapy spray, inhalant, cream, patch and other care products, with good application prospect.

The invention relates to the technical field of medicine preparation, in particular to burka granules, a preparation process and application of the burka granules in preparation of antipyretic, anti-inflammatory and cough-relieving medicines. According to the invention, the medicine for treating and preventing the heat type common cold is obtained by adopting the burka particles for the first time, and has the characteristics of rapid efficacy, long shelf life of the efficacy, stable efficacy and convenience in taking; the love granules provided by the invention have the curative effects of clearing heat, diminishing inflammation, relieving cough and the like in animal experiments. The traditional Chinese medicine composition has the effects of conditioning abnormal bile fluid, abating fever and dredging obstruction in clinical application, is used for sweating of fever infectious diseases, cold, cough, pharyngitis and the like, and has a good application prospect in medicines for preventing and / or treating influenza and acute upper respiratory infection. Meanwhile, the preparation method is safe, simple and convenient, and compared with a traditional preparation, the medicine compliance can be obviously improved. The prepared burka granules disclosed by the invention are convenient to store and transport.

The invention provides a polypeptide and application thereof in preparation of an anti-influenza virus infection product. The amino acid sequence of the polypeptide is shown as any one of SEQ ID NO: 1-3. The polypeptide provided by the invention has excellent anti-influenza virus activity, can effectively inhibit influenza virus activity at low concentration, and is low in cytotoxicity, high in selectivity index and good in safety. The polypeptide provided by the invention is inactivated by directly destroying the envelope of influenza virus, has an action mechanism different from that of the existing anti-influenza drugs targeting virus enzymes, is not easy to generate cross resistance with the existing drugs, and is small in molecular weight, clear in structure, easy to chemically synthesize and modify and suitable for industrial production. And a solid foundation is laid for the subsequent development of novel anti-influenza drugs.

A method and use of Zeolite and Polyethylenimine (PEI) Polymer coated air filtration media designed to absorb CH4 and CO2 and a method and use of Polyacrylonitrile (PAN), Iodine, Vinegar, Resveratrol, Interferon and Zeolite coated disposable respirator media designed to absorb airborne deleterious pollutants such as PM2.5 and biological agents such as Influenza, COVID-SARS and Avian Pox viruses and bacteria and protect the wearer from inhalation of said pollutant and deleterious agents.

The invention discloses a traditional Chinese medicine composition for treating influenza as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 70 to 98 parts of honey-fried herba ephedrae, 180 to 240 parts of honeysuckle flower, 250 to 310 parts of semen lepidii, 180 to 240 parts of rhizoma cimicifugae, 180 to 240 parts of cortex moutan, 380 to 460 parts of gypsum, 180 to 240 parts of honey-fried cortex mori, 180 to 240 parts of radix scutellariae, 180 to 240 parts of radix scrophulariae, 180 to 240 parts of radix rehmanniae recen and 180 to 240 parts of rhizoma atractylodis macrocephalae fried with bran. According to the invention, a multi-dimensional compatibility system for relieving exterior syndrome and eliminating evil, clearing away heat and toxic materials, freeing lung and relieving asthma, and cooling blood and protecting lung is constructed on the basis of the core pathogenesis of influenza of exogenous evil toxin, heat toxin invading lung and lung dysfunction, and all traditional Chinese medicines perform their own functions to form a synergistic treatment effect on influenza virus invasion and lung injury; the problem that a single-effect traditional Chinese medicine is difficult to comprehensively deal with the complex pathological process of influenza is solved.